Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 13/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15844077 | 0.87 | CACNA1H (0.56) | CACNA1HCACNA1GLMNATSHRPOLB | |
| SCHEMBL15844374 | 0.86 | CACNA1H (0.70) | CACNA1HCACNA1GCACNA1BLMNATSHR | |
| SCHEMBL15844419 | 0.85 | CACNA1H (0.54) | CACNA1HCACNA1GLMNATSHR | |
| SCHEMBL15844275 | 0.85 | CACNA1H (0.54) | CACNA1HCACNA1GLMNATSHRPKM | |
| SCHEMBL17437406 | 0.83 | CACNA1H (0.76) | CACNA1HCACNA1GCACNA1B | |
| SCHEMBL3427756 | 0.76 | EGLN1 (0.42) | CACNA1HCACNA1GCACNA1B | |
| SCHEMBL18761295 | 0.76 | CACNA1H (0.56) | CACNA1HCACNA1GTNKSPARP1PARP2 | |
| Lithium Ion SCHEMBL3427753 | 0.75 | CACNA1H (0.41) | CACNA1HCACNA1GCACNA1B | |
| SCHEMBL20094226 | 0.74 | LMNA (0.53) | CACNA1HCACNA1GLMNATSHRMEN1 | |
| SCHEMBL20094224 | 0.74 | CACNA1H (0.57) | CACNA1HLMNATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPV1, SCN1A | CACNA1H 32/4885CACNA1G 13/4885CACNA1B 9/4885 |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | CACNA1H 20/4885CACNA1G 7/4885CACNA1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.